WASHINGTON and ATLANTA -- As of July 10, 2003, the Centers for Disease Control and Prevention (CDC) removed its travel alert for Hong Kong and Toronto, Canada to reflect the changing status of Severe Acute Respiratory Syndrome (SARS) cases reported in these areas. The alert for Hong Kong is lifted retroactively for 1 July 2003 (last case of onset based on updated research in Hong Kong determined to be May 31). The alerts for Hong Kong and Toronto, Canada were lifted because more than 30 days had elapsed since the date of onset of symptoms for the last SARS case.
In response to the SARS epidemic, CDC issues two types of notices to travelers: alerts and advisories. A travel advisory recommends that nonessential travel be deferred; a travel alert does not advise against travel, but informs travelers of a health concern and provides advice about specific precautions. Recommendations to postpone travel or observe precautions are issued in consideration of several factors, including the magnitude of current SARS cases, the pattern of recent local transmission, and the last date of onset of cases.
Beijing and Taiwan are the remaining areas under CDC's travel alert. CDC continues to distribute health alert notices about SARS to people traveling to the United States from these areas. Individuals who travel to Beijing and Taiwan, should monitor their health while there and for at least 10 days after departure. If fever or respiratory symptoms (for example, cough or shortness of breath) develop, a visit to a healthcare provider is strongly recommended. The provider should be informed about the symptoms in advance so arrangements can be made, if necessary, to prevent transmission to others in the healthcare setting.
For more information, visit: http://www.cdc.gov/ncidod/sars/index.htm.
Source: CDC
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.